Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

DMP 696

Known as: 4-(1,3-dimethoxy-2-propylamino)-2,7-dimethyl-8-(2,4-dichlorophenyl)(1,5-a)pyrazolo-1,3,5-triazine, DMP-696, DMP696 
 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

PyrazolesTriazines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Consolidation of Remote Fear Memories Involves Corticotropin-Releasing Hormone (CRH) Receptor Type 1-Mediated Enhancement of AMPA Receptor GluR1 Signaling in the Dentate Gyrus
Persistent dreadful memories and hyperarousal constitute prominent psychopathological features of posttraumatic stress disorder… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2007
Highly Cited
2007
Persistent neuroendocrine and behavioral effects of a novel, etiologically relevant mouse paradigm for chronic social stress during adolescence
Chronic stress is widely regarded as a key risk factor for a variety of diseases. A large number of paradigms have been used to… Expand
Highly Cited
2007
Highly Cited
2007
Activation of basolateral amygdala corticotropin-releasing factor 1 receptors modulates the consolidation of contextual fear
The basolateral amygdala complex (BLA) and central amygdala nucleus (CeA) are involved in fear and anxiety. In addition, the BLA… Expand
Highly Cited
2006
Highly Cited
2006
Proteomic analysis of rat hippocampus and frontal cortex after chronic treatment with fluoxetine or putative novel antidepressants: CRF1 and NK1 receptor antagonists
Chronic administration of antidepressants is required for their efficacy, suggesting the involvement of long-term modifications… Expand
Review
2005
Review
2005
The pharmacology of DMP696 and DMP904, non-peptidergic CRF1 receptor antagonists.
CRF(1) antagonists DMP696 and DMP904 were designed as drug development candidates for the treatment of anxiety and depression… Expand
2004
2004
Differential regulation of behavioral, genomic, and neuroendocrine responses by CRF infusions in rats
Studies suggest that behavioral, genomic, and endocrine functions mediated by central corticotropin-releasing factor (CRF… Expand
Highly Cited
2003
Highly Cited
2003
Receptor Occupancy of Nonpeptide Corticotropin-Releasing Factor 1 Antagonist DMP696: Correlation with Drug Exposure and Anxiolytic Efficacy
4-(1,3-Dimethoxyprop-2-ylamine)-2,7-dimethyl-8-(2,4-dichlorophenyl)-pyrazolo[1,5-a]-1,3,5-triazine (DMP696) is a highly selective… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 6
Highly Cited
2002
Highly Cited
2002
Effects of a Non-peptide CRF Antagonist (DMP696) on the Behavioral and Endocrine Sequelae of Maternal Separation
We examined whether blockade of corticotropin-releasing factor (CRF) receptors by a non-peptide CRF antagonist (DMP696) would… Expand
  • figure 2
  • figure 3
  • table 1
  • figure 4
2002
2002
The CRF1 receptor antagonist DMP696 produces anxiolytic effects and inhibits the stress-induced hypothalamic-pituitary-adrenal axis activation without sedation or ataxia in rats
Abstract Rationale. CRF1 antagonists may be effective in the treatment of anxiety disorders while having fewer side effects… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2000
Highly Cited
2000
4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.
Structure-activity studies in the pyrazolo[1,5-a]-1,3,5-triazine series led to the discovery that compound 11i (DMP696) is a… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE